Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|February 9, 2021
Nouveau short-course therapy and morphism mapping for clinical pulmonary <i>Mycobacterium kansasii</i>Shashikant Srivastava, Jann-Yuan Wang, Gesham Magombedze, et al.
Frontiers in Pharmacology|August 28, 2020
Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic StudyIsaac Zentner, Hyun-Moon Back, Leonid Kagan, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Antibacterial and Sterilizing Effect of Benzylpenicillin in TuberculosisDevyani Deshpande, Shashikant Srivastava, Paula Bendet, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2017
Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TBChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Plos One|November 3, 2017
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Stellah G Mpagama, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2014
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosisEmmanuel Chigutsa, Jotam G Pasipanodya, Marianne E Visser, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2021
Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosisRichard Court, Chad M Centner, Maxwell Chirehwa, et al.
Science Advances|September 7, 2017
Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosisDevyani Deshpande, Shashikant Srivastava, Moti Chapagain, et al.
British Journal of Clinical Pharmacology|October 30, 2016
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|February 9, 2021
Nouveau short-course therapy and morphism mapping for clinical pulmonary <i>Mycobacterium kansasii</i>Shashikant Srivastava, Jann-Yuan Wang, Gesham Magombedze, et al.
Frontiers in Pharmacology|August 28, 2020
Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic StudyIsaac Zentner, Hyun-Moon Back, Leonid Kagan, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Antibacterial and Sterilizing Effect of Benzylpenicillin in TuberculosisDevyani Deshpande, Shashikant Srivastava, Paula Bendet, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2017
Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TBChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Plos One|November 3, 2017
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Stellah G Mpagama, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2014
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosisEmmanuel Chigutsa, Jotam G Pasipanodya, Marianne E Visser, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2021
Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosisRichard Court, Chad M Centner, Maxwell Chirehwa, et al.
Science Advances|September 7, 2017
Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosisDevyani Deshpande, Shashikant Srivastava, Moti Chapagain, et al.
British Journal of Clinical Pharmacology|October 30, 2016
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Pageof 21